Deferred Tax Assets, Net of Valuation Allowance of Vistagen Therapeutics, Inc. from 31 Mar 2016 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
Vistagen Therapeutics, Inc. quarterly Deferred Tax Assets, Net of Valuation Allowance in USD history and change rate from 31 Mar 2016 to 31 Mar 2025.
  • Vistagen Therapeutics, Inc. Deferred Tax Assets, Net of Valuation Allowance for the quarter ending 31 Mar 2025 was $24,000, a 20% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Change (%)

Vistagen Therapeutics, Inc. Quarterly Deferred Tax Assets, Net of Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $24,000 +$4,000 +20% 31 Mar 2025 10-K 17 Jun 2025 2025 FY
Q1 2024 $20,000 +$15,000 +300% 31 Mar 2024 10-K 17 Jun 2025 2025 FY
Q1 2023 $5,000 +$5,000 31 Mar 2023 10-K 11 Jun 2024 2024 FY
Q1 2022 $0 $0 31 Mar 2022 10-K 28 Jun 2023 2023 FY
Q1 2021 $0 $0 31 Mar 2021 10-K 23 Jun 2022 2022 FY
Q1 2020 $0 $0 31 Mar 2020 10-K 29 Jun 2021 2021 FY
Q1 2019 $0 $0 31 Mar 2019 10-K 29 Jun 2020 2020 FY
Q1 2018 $0 $0 31 Mar 2018 10-K 25 Jun 2019 2019 FY
Q1 2017 $0 $0 31 Mar 2017 10-K 26 Jun 2018 2018 FY
Q1 2016 $0 31 Mar 2016 10-K 29 Jun 2017 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.